This investment brings the total equity raised by Presage to date to $35 million.
- This investment brings the total equity raised by Presage to date to $35 million.
- "Presage's CIVO technology and unique approach to early anticancer drug evaluation represent a potential solution that typical preclinical models cannot address."
- Presage has ongoing collaborations with Takeda and other large pharmaceutical organizations for Phase 0 trials with CIVO.
- Presage also partners with oncology-focused pharmaceutical companies through strategic alliances to provide preclinical data to discover effective drug combinations.